Showing results (1261-1270 of 4,516) with videos related to

Sort By:
Pageof 452
Future Oncology (London, England)|December 2, 2021
Serum exosomal miR-377-3p and miR-381-3p as diagnostic biomarkers in colorectal cancerLi Wang, Xingguo Song, Miao Yu, et al.
Future Oncology (London, England)|December 2, 2021
Unsupervised learning of cross-modal mappings in multi-omics data for survival stratification of gastric cancerJianmin Xu, Yueping Yao, Binghua Xu, et al.
Future Oncology (London, England)|December 6, 2021
Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature reviewYing Zheng, Helene Vioix, Frank X Liu, et al.
Future Oncology (London, England)|December 7, 2021
Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysisYang Cheng, Chong Wang, Yan Wang, et al.
Future Oncology (London, England)|September 22, 2022
Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2Shom Goel, Antoinette R Tan, Hope S Rugo, et al.
Future Oncology (London, England)|September 13, 2022
Real-world outcomes in patients with first-line and second-line therapy for advanced esophageal squamous cell carcinomaDaniel Ahn, Michelle Sidel, Laura Panattoni, et al.
Future Oncology (London, England)|September 14, 2022
MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphomaChristine E Ryan, Matthew S Davids, Richard Hermann, et al.
Future Oncology (London, England)|December 14, 2021
Adenoid cystic carcinoma of the breast and intraoperative electron radiotherapy: single case report and review of literatureGiuseppe Accardo, Alba Ml Capobianco, Giuseppe La Torre, et al.
Future Oncology (London, England)|December 17, 2021
INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistanceEgbert F Smit, Christophe Dooms, Jo Raskin, et al.
Future Oncology (London, England)|December 9, 2021
IL-6 and IL-8 cytokines are associated with elevated prostate-specific antigen levels among patients with adenocarcinoma of the prostate at the Uganda Cancer InstitutePaul Katongole, Obondo J Sande, Sheilla Nabweyambo, et al.
Pageof 452